目的分析体外诱导的NY-ESO-1特异性杀伤性T淋巴细胞对稳定表达NY-ESO-1蛋白的肝细胞性肝癌(hepatocellular carcinoma,HCC)细胞系的杀伤效应,为进一步分析NY-ESO-1蛋白作为疫苗用于治疗HCC的可能性提供实验支持。
基于4个网页-相关网页
A 22鼠腹水肝癌细胞和鼠正常肝细胞膜脂的运动性。
A22 mouse ascites cell membrane lipids and those of the control cells.
肝细胞性肝癌是发病和死亡的常见原因。对于不能手术切除肿瘤的患者，予全身化疗是标准治疗方案之一。
HCC is a common cause of morbidity and mortality. For patients who are not candidates for curative surgery, systemic chemotherapy is one of the standard treatments.
持续病毒学应答可以降低肝硬化和肝病并发症的发生，降低肝癌(肝细胞性癌)和死亡的发生率。
Sustained virologic response can result in decreased cirrhosis and complications of liver disease, decreased rates of liver cancer (hepatocellular carcinoma), and decreased mortality.
应用推荐